Mark Philip Breazzano MD FACS

Clinical Trials

• OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) Start of enrollment: 2021 Mar 12

  TERMINATED

  PHASE3

• A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment Start of enrollment: 2023 Apr 04

  Completed

  Phase 2

• Fenofibrate for Prevention of DR Worsening Start of enrollment: 2021 Mar 05

  Recruiting

  Phase 3

• Evaluation of Tonabersat for DME Start of enrollment: 2023 May 02

  ACTIVE_NOT_RECRUITING

  PHASE2

• Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM Start of enrollment: 2022 Feb 22

  RECRUITING

  NA

• Nesvategrast (OTT166) in Diabetic Retinopathy (DR) Start of enrollment: 2022 Jul 29

  COMPLETED

  PHASE2

• A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) Start of enrollment: 2023 Mar 06

  ACTIVE_NOT_RECRUITING

  PHASE2

• GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) Start of enrollment: 2019 Jan 08

  TERMINATED

• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Start of enrollment: 2018 Sep 05

  COMPLETED

  PHASE3

• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) Start of enrollment: 2019 Feb 19

  COMPLETED

  PHASE3

• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema Start of enrollment: 2020 Aug 05

  COMPLETED

  PHASE3

• RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE) Start of enrollment: 2020 Aug 25

  RECRUITING

  PHASE2

• A Study of NGM621 in Participants With Geographic Atrophy Start of enrollment: 2020 Jul 22

  COMPLETED

  PHASE2

• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Start of enrollment: 2021 Mar 02

  COMPLETED

  PHASE3

• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Start of enrollment: 2021 Mar 02

  COMPLETED

  PHASE3

• A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) Start of enrollment: 2019 Jun 03

  Terminated

  Phase 2

• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) Start of enrollment: 2021 Dec 14

  RECRUITING

  PHASE4

• FIGHT-RP 1 Extension Study Start of enrollment: 2019 Jun 24

  ACTIVE_NOT_RECRUITING

  PHASE1

• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration Start of enrollment: 2021 Apr 19

  COMPLETED

  PHASE3

• RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) Start of enrollment: 2020 Nov 20

  RECRUITING

  PHASE2

• A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) Start of enrollment: 2021 Oct 19

  ACTIVE_NOT_RECRUITING

  PHASE2, PHASE3

• A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema Start of enrollment: 2020 Jul 31

  Completed

  Phase 2

• Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Start of enrollment: 2022 Sep 26

  COMPLETED

  PHASE3

• Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) Start of enrollment: 2022 Jul 28

  COMPLETED

  PHASE2

• Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration Start of enrollment: 2020 Oct 28

  RECRUITING

  PHASE1, PHASE2

• A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) Start of enrollment: 2023 Jun 12

  COMPLETED

  PHASE1, PHASE2

• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema Start of enrollment: 2024 Jan 09

  RECRUITING

  PHASE2

• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration Start of enrollment: 2024 Jan 31

  RECRUITING

  PHASE2

• A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products Start of enrollment: 2022 Nov 21

  RECRUITING

• A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) Start of enrollment: 2024 Jan 24

  COMPLETED

  PHASE3

• Join now to see all